• Florida reported record number of new COVID-19 cases
• Tesla (TSLA.US) stock hit fresh all-time high
US indices started the week on a positive note, as investors digest recent spike in COVID-19 cases. Yesterday Florida recorded a record increase of more than 15,000 new coronavirus cases, more than hard-hit New York state at the peak of its crisis in April. However markets turn their attention to corporate earnings season to grasp the impact of the pandemic on companies. According to analysts' expectations, S&P 500 index second-quarter earnings will be approximately 45% lower compare to the same quarter last year. Goldman Sachs (GS.US) has become a little more optimistic on earnings prospects this year, lifting its baseline forecast for S&P 500 earnings per share in 2020 to $115, up from a prior estimate of $110. Today Pepsi Co (PEP.US) reported better than expected earnings results. BioNTech (BNTX.US) and Pfizer (PFE.US) shares rose as two of their experimental coronavirus vaccines received the US FDA's 'fast track' designation, and could be ready for approval by the end of October. A lot of major US companies will release earnings this week including JPMorgan, Citigroup, Wells Fargo, Goldman Sachs, Netflix, IBM, Johnson & Johnson, UnitedHealth, and Blackrock. There are no major, market moving data scheduled for release today, but tomorrow investors will get to know U.S. consumer inflation data for June, while retail sales, a key gauge of consumption, are released on Thursday.


"Marketing is being given a complete re-appraisal and G&A is also being looked at now that the worst of the crisis is behind the company. Finally, DRI's cash position allows flexibility as the crisis continues whether for a scale-benefitting well-priced acquisition or reinstatement of the dividend." JPMorgan increases its price target on DRI to $82 from $74 to value Darden at 14X the firm's 2022 EPS estimate. The average sell-side PT is $85.52. Shares of Darden are up 2.65% premarket to $74.00.
Moderna (MRNA.US) was rated a “buy” by Jefferies, based on its expectation that the drugmaker's Covid-19 vaccine candidate will be approved and that it could generate about $5 billion in orders over the next few years.
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.